GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker

Clinics

Volumn 66, Issue 6, 2011, Pages 965-972

  Carvalho, Kátia C ^a   Cunha, Isabela W ^b   Rocha, Rafael M ^b   Ayala, Fernanda R ^b   Cajaíba, Mariana M ^b   Begnami, Maria D ^b   Vilela, Rafael S ^b   Paiva, Geise R ^b   Andrade, Rodrigo G ^b   Soares, Fernando A ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Glucose transporter 1; Immunohistochemistry; Malignant tumors; PET scan; Protein expression

Indexed keywords

GLUCOSE TRANSPORTER 1; TUMOR MARKER;

ARTICLE; CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROEPITHELIOMA; PREDICTIVE VALUE; PROGNOSIS; TISSUE MICROARRAY;

CARCINOMA; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, NEUROEPITHELIAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79961152254     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000600008     Document Type: Article

References (70)

1. Isselbacher KJ. Sugar and amino acid transport by cells in culturedifferences between normal and malignant cells. N Engl J Med. 1972;286:929-933, doi: 10.1056/NEJM197201062860111.
2. Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab. 2010;298:E141-E145, doi: 10.1152/ajpendo.00712.2009.
3. Kim YW, Do IG, Park YK. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathol Res Pract. 2006;202:759-765, doi: 10.1016/j.prp.2006.07.006.
4. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science. 1987;235:1495-1498, doi: 10.1126/science.3029870.
5. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 2001;104:517-529, doi: 10.1016/S0092-8674(01)00239-2.
6. Furuta E, Okuda H, Kobayashi A, Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta. 2010;1805:141-152.
7. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314, doi:10.1126/science.123.3191.309.
8. Vazquez A, Liu J, Zhou Y, Oltvai ZN. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst Biol. 2010;4:58. doi:10.1186/17520509-4-58., doi: 10.1186/1752-0509-4-58
9. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033, doi: 10.1126/science.1160809.
10. Stokkel MP, Linthorst MF, Borm JJ, Taminiau AH, Pauwels EK. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J Cancer Res Clin Oncol. 2002;128:393-399, doi: 10.1007/s00432-002-0350-5.
11. Suganuma N, Segade F, Matsuzu K, Bowden DW. Differential expression of facilitative glucose transporters in normal and tumor kidney tissues. BJU Int. 2007;99:1143-1149, doi: 10.1111/j.1464-410X.2007.06765.x.
12. North PE, Waner M, Mizeracki A, Mihm MC Jr. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31:11-22, doi: 10.1016/S0046-8177(00)80192-6.
13. North PE, Waner M, Mizeracki A, Mrak RE, Nicholas R, Kincannon J, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137:1-12.
14. Drut R, Altamirano E. Endothelial cells of intramuscular (infantile) hemangioma express glut1. Int J Surg Pathol. 2007;15:166-168, doi: 10.1177/1066896906299123.
15. Badi AN, Kerschner JE, North PE, Drolet BA, Messner A, Perkins JA. Histopathologic and immunophenotypic profile of subglottic hemangioma: multicenter study. Int J Pediatr Otorhinolaryngol. 2009;73:1187-191, doi: 10.1016/j.ijporl.2009.03.024.
16. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223-230, doi: 10.1016/0006-291X(90)91263-R.
17. Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H, et al. Distribution of the glucose transporters in human brain tumors. Cancer Res. 1992;52:3972-3979.
18. Brown RS, Wahl RL. Overexpression of GLUT-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer. 1993;72:2979-2985, doi: 10.1002/1097-0142(19931115)72:10,2979::AIDCNCR2820721020.3.0.CO;2-X.
19. Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol. 1995;153:798-801, doi: 10.1016/S0022-5347(01)67725-5.
20. Baer SC, Casaubon L, Younes M. Expression of the human erythrocyte glucose transporte GLUT-1 in cutaneous neoplasia. J Am Acad Dermatol.1997;37:575-577, doi: 10.1016/S0190-9622(97)70174-9.
21. Ogawa J, Inoue H, Koide S. Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer. 1997;74:189-192, doi: 10.1002/(SICI)1097-0215-(19970422)74:2,189::AID-IJC9.3.0.CO;2-V.
22. Haber R, Rathan A, Weiser KR. GLUT-1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40, doi: 10.1002/(SICI)1097-0142(19980701)83:1,34::AID-CNCR5.3.0.CO;2-E.
23. Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE. Immunohistochemical staining of GLUT1 in benign, hyperplastic and malignant endometrial epithelia. Cancer. 2000;88:2774-2781, doi: 10.1002/1097-0142(20000615)88:12,2774::AID-CNCR16.3.0.CO;2-I.
24. Cantuária G, Fagotti A, Ferrandina G. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001;92:1144-1150, doi: 10.1002/1097-0142(20010901)92:5,1144::AIDCNCR1432.3.0.CO;2-T.
25. Rudlowski C, Becker AJ, Schroder W, Rath W, Büttner R, Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol. 2003;20:691-698, doi:10.1309/4KYNQM5862JW2GD7.
26. Birnbaum MJ, Haspel HC, Rosen OM. Cloning and characterization of a cDNA encoding the rat brain glucose-transporter protein. Proc Natl Acad Sci USA. 1986;83:5784-5788, doi: 10.1073/pnas.83.16.5784.
27. Fukumoto H, Seino S, Imura H, Seino Y, Bell GI. Characterization and expression of human HepG2/erythrocyte glucose transporter gene. Diabetes. 1988;37:657-661, doi: 10.2337/diabetes.37.5.657.
28. Oliver RJ, Woodwards RTN, Sloan P, Thakker NS, Stratford IJ, Airley RE. Prognostic value of facilitative glucose transporter GLUT-1 in oral squamous cell carcinoma treated by surgical resection: results of Eortc Translational Research Fund Studies. Eur J Cancer. 2003;13:503-507.
29. Dierckx RA, Van de Wiele C. FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging. 2008;35:1544-1549, doi: 10.1007/s00259-008-0758-5.
30. Usuda K, Sagawa M, Aikawa H, Ueno M, Tanaka M, Machida Y, et al. Correlation between glucose transporter-1 expression and 18F-fluoro-2- deoxyglucose uptake on positron emission tomography in lung cancer. Gen Thorac Cardiovasc Surg. 2010;58:405-410, doi: 10.1007/s11748-10-0603-1.
31. Buim ME, Lourenco SV, Carvalho KC, Cardim R, Pereira C, Carvalho AL, et al. Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. Oral Oncol. 2010;46:166-171, doi: 10.1016/j.oraloncology.2009.11.009.
32. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16:919-928, doi: 10.1677/ERC-08-0211.
33. Nakajo M, Kajiya Y, Tani A, Yoneda S, Shirahama H, Higashi M, et al. (18)FDG PET for grading malignancy in thymic epithelial tumors: significant differences in (18)FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study. Eur J Radiol. 2010;doi: 10.1016/j.ejrad.2010.08.010.
34. Kallinowski E, Schienger KH, Kunkel S. Blood flow, metabolism, cellular microenvironment and growth rate of human tumor xenography. Cancer Res. 1989;49:3759-3764.
35. Chiche J, Brahimi-Horn MC, Pouysségur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell MolMed. 2010;14:771-794, doi: 10.1111/j.1582-4934.2009.00994.x.
36. Heber D, Byerley LD, Tchekmedyian NS. Hormonal and metabolic abnormalities in the malnourished cancer patients: effects on host-tumor interaction. J PEN J Parenter Enteral Nutr. 1992;16:60-64, doi: 10.1177/014860719201600605.
37. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol.2005;202:654-662, doi: 10.1002/jcp.20166.
38. Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci. 1999;56:285-292.
39. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007;53:233-256, doi:10.1159/000104457.
40. Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97:2035-2042, doi: 10.1002/cncr.11293.
41. Jans J, van Dijk JH, van Schelven S, van der Groep P, Willems SH, Jonges TN, et al. Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology. 2010;75:786-792, doi: 10.1016/j.urology.2009.08.024.
42. Khandani AH, Funkhouser WK, Feins R, Socinski MA. Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer. Ann Nucl Med. 2009;23:595-597, doi: 10.1007/s12149-009-0264-2.
43. Takanaga H, Frommer WB. Facilitative plasma membrane transporters function during ER transit. FASEB J. 2010;24:2849-2858, doi: 10.1096/fj.09-146472.
44. Yasuda M, Naoki O, Hayashi H. Glucose transporter-1 expression in the thyroid gland: clinocopathological significance for papillary carcinoma. Oncol Rep. 2005;14:1499-1504.
45. Ciampi R, Vivaldi A, Romei C, Del Guerra A, Salvadori P, Cosci B, et al. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol. 2008;291:57-62, doi: 10.1016/j.mce.2008.05.003.
46. Kawamura T, Kusakabe T, Sugino T. Expression of glucose transporter-1 in human gastric carcinoma. Cancer. 2001;92:634-641, doi: 10.1002/1097-0142(20010801)92:3,634::AID-CNCR1364.3.0.CO;2-X.
47. Wei B, Chen L, Li J. Expression of glucose transporter 1 in gastric carcinoma and metastatic lymph nodes and its association with prognosis. Zhonghua Wei Chang Wai Ke Za Zhi. 2009;12:277-280.
48. Binder C, Binder L, Marx D, Schauer A, Hiddemann W. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res. 1997;17:4299-4304.
49. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16.
50. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387, doi: 10.1200/JCO.20.2.379.
51. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol. 2002;29:443-453, doi: 10.1016/S0969-8051(02)00288-3.
52. Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res. 2002;93:1123-11228.
53. Ravazoula P, Batistatou A, Aletra C, Ladopoulos J, Kourounis G, Tzigounis B. Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur J Gynaecol Oncol. 2003;24:544-546.
54. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer. 2007;97:646-653, doi: 10.1038/sj.bjc.6603922.
55. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15:2895-2898.
56. Hao LS, Ni Q, Jia GQ, Wang G, Qian K, Liu YJ, et al. Expression of lucose transporter 1 in human breast carcinoma and its clinical significance. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40:44-47.
57. Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, et al. (18)F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2010 Aug 14. doi: 10.1007/s00259-010-1590-2
58. Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA, et al. The XbaI G.T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer. J Nucl Med. 2010;51:1191-1197, doi: 10.2967/jnumed.110.075721.
59. Baer S, Casaubon L, Schwartz MR, Macrogliese A, Younes M. GLUT-3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngosope. 2002;112:393-396, doi: 10.1097/00005537-200202000-00034.
60. Reisser C, Eichhorn K, Herold-Mende C, Born AI, Bannasch P. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer. 1999;80:194-198, doi: 10.1002/(SICI)1097-0215(19990118)80:2,194::AIDIJC6.3.0.CO;2-M.
61. Ayala FR, Rocha RM, Carvalho KC, Carvalho AL, da Cunha IW, Lourenço SV, et al. GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules. 2010;15:2374-2387, doi: 10.3390/molecules15042374.
62. Wachsberger PR, Gressen EL, Bhala A, Bobyock SB, Storck C, Coss RA, et al. Variability in glucose transporter-1 levels and hexokinase activity in human melanoma. Melanoma Res. 2002;12:35-43, doi: 10.1097/00008390-200202000-00006.
63. Rao UN, Finkelstein SD, Jones MW. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas. Mod Pathol. 1999;12:1001-1009.
64. Minamimoto R, Senda M, Terauchi T, Jinnouchi S, Inoue T, Iinuma T, et al. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey. Ann Nucl Med. 2010 Oct 17. doi: 10.1007/s12149-010-0428-0.
65. Storto G, Di Giorgio E, De Renzo A, Pizzuti LM, Cerciello G, Nardelli A, et al. Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. Br J Haematol. 2010;151:195-197 doi: 10.1111/j.1365-2141.2010.08335.x, doi: 10.1111/j.1365-2141.2010.08335.x.
66. Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97:2035-2042, doi: 10.1002/cncr.11293.
67. Amann T, Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets. 2009;13:1411-1427, doi: 10.1517/14728220903307509.
68. De Jong IJ, De Haan TD, Wiegman EM, Van Den Bergh AC, Pruim J, Breeuwsma AJ. PET/CT and radiotherapy in prostate cancer. Q J Nucl Med Mol Imaging. 2010;54:543-552.
69. Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr. 2010;34:479-484, doi:10.1097/RCT.0b013e3181db2670
70. Ho CL, Chen S, Cheng TK, Leung YL. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology. 2010 Nov 9. doi:10.1148/radiol.10100672.